Alogliptin Benzoate is a selective DPP-4 inhibitor that prolongs incretin hormone activity to enhance glucose-dependent insulin secretion, used in the management of type 2 diabetes. Simson Pharma's Alogliptin Benzoate reference standard and impurities support generic development within this established oral antidiabetic class.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Alogliptin Benzoate Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.